{"id":1765,"date":"2020-06-14T16:35:23","date_gmt":"2020-06-14T16:35:23","guid":{"rendered":"https:\/\/magazines.uthscsa.edu\/cancer-center\/?p=1765"},"modified":"2020-06-16T21:00:12","modified_gmt":"2020-06-16T21:00:12","slug":"fda-approves-drug-to-treat-blood-cancer","status":"publish","type":"post","link":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/","title":{"rendered":"FDA approves new drug to treat rare blood cancer myelofibrosis"},"content":{"rendered":"<p>The\u00a0U.S. Food and Drug Administration recently approved the first new medication in nearly a decade for patients with myelofibrosis, a rare blood cancer.<\/p>\n<p>Ruben Mesa, M.D., FACP, director of the Mays Cancer Center, was part of the international research team that led development of the new drug.<\/p>\n<p>Due to the drug\u2019s effectiveness in treating myelofibrosis, fedratinib (brand name Inrebic) is being studied to see if it may also be beneficial for patients with other blood cancers, inflammatory diseases and possibly, one day, for diseases related to aging or that involve blood clots, such as heart attacks or stroke.<\/p>\n<p>The FDA approved fedratinib for adults with intermediate-2 or high-risk primary or secondary myelofibrosis. Myelofibrosis is a blood cancer that begins in the bone marrow, where red blood cells, white blood cells and platelets are made.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mays Cancer Center director is part of an international research team that developed a new drug to treat myelofibrosis, a rare blood cancer. The U.S. Food and Drug Administration approved the new drug. <\/p>\n","protected":false},"author":43,"featured_media":1833,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,12],"magazine":[22],"issue-year":[44],"featured-story":[],"class_list":["post-1765","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-patient-care","category-research","magazine-cancer-center","issue-year-44"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA approves new drug to treat rare blood cancer myelofibrosis - Mays Cancer Center Annual Report<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA approves new drug to treat rare blood cancer myelofibrosis - Mays Cancer Center Annual Report\" \/>\n<meta property=\"og:description\" content=\"Mays Cancer Center director is part of an international research team that developed a new drug to treat myelofibrosis, a rare blood cancer. The U.S. Food and Drug Administration approved the new drug.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Mays Cancer Center Annual Report\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-14T16:35:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-16T21:00:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2020\/06\/Mesa_featured.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"duncancl\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"duncancl\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/\"},\"author\":{\"name\":\"duncancl\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/#\\\/schema\\\/person\\\/92ba77ef72a0095914424aa87b09c99c\"},\"headline\":\"FDA approves new drug to treat rare blood cancer myelofibrosis\",\"datePublished\":\"2020-06-14T16:35:23+00:00\",\"dateModified\":\"2020-06-16T21:00:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/\"},\"wordCount\":148,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/2020\\\/06\\\/Mesa_featured.jpg\",\"articleSection\":[\"Patient Care\",\"Research\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/\",\"name\":\"FDA approves new drug to treat rare blood cancer myelofibrosis - Mays Cancer Center Annual Report\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/2020\\\/06\\\/Mesa_featured.jpg\",\"datePublished\":\"2020-06-14T16:35:23+00:00\",\"dateModified\":\"2020-06-16T21:00:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/#\\\/schema\\\/person\\\/92ba77ef72a0095914424aa87b09c99c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/2020\\\/06\\\/Mesa_featured.jpg\",\"contentUrl\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/2020\\\/06\\\/Mesa_featured.jpg\",\"width\":800,\"height\":480,\"caption\":\"Ruben Mesa, M.D., FACP\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2020\\\/06\\\/14\\\/fda-approves-drug-to-treat-blood-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mays Cancer Center Annual Report\",\"item\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/magazine\\\/cancer-center\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FDA approves new drug to treat rare blood cancer myelofibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/#website\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/\",\"name\":\"Mays Cancer Center Annual Report\",\"description\":\"Mays Cancer Center Annual Reports\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/#\\\/schema\\\/person\\\/92ba77ef72a0095914424aa87b09c99c\",\"name\":\"duncancl\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4561cd958c8f1ae172cfa6e6a22ea689cad8a0153177b8c4b0997fa83e7bbe33?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4561cd958c8f1ae172cfa6e6a22ea689cad8a0153177b8c4b0997fa83e7bbe33?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4561cd958c8f1ae172cfa6e6a22ea689cad8a0153177b8c4b0997fa83e7bbe33?s=96&d=mm&r=g\",\"caption\":\"duncancl\"},\"description\":\"Catherine Duncan is director of communications for the Office of Institutional Advancement. She also serves as editor and publications director for Salute magazine.\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/author\\\/duncancl\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA approves new drug to treat rare blood cancer myelofibrosis - Mays Cancer Center Annual Report","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/","og_locale":"en_US","og_type":"article","og_title":"FDA approves new drug to treat rare blood cancer myelofibrosis - Mays Cancer Center Annual Report","og_description":"Mays Cancer Center director is part of an international research team that developed a new drug to treat myelofibrosis, a rare blood cancer. The U.S. Food and Drug Administration approved the new drug.","og_url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/","og_site_name":"Mays Cancer Center Annual Report","article_published_time":"2020-06-14T16:35:23+00:00","article_modified_time":"2020-06-16T21:00:12+00:00","og_image":[{"width":800,"height":480,"url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2020\/06\/Mesa_featured.jpg","type":"image\/jpeg"}],"author":"duncancl","twitter_card":"summary_large_image","twitter_misc":{"Written by":"duncancl","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/#article","isPartOf":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/"},"author":{"name":"duncancl","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/#\/schema\/person\/92ba77ef72a0095914424aa87b09c99c"},"headline":"FDA approves new drug to treat rare blood cancer myelofibrosis","datePublished":"2020-06-14T16:35:23+00:00","dateModified":"2020-06-16T21:00:12+00:00","mainEntityOfPage":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/"},"wordCount":148,"commentCount":0,"image":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2020\/06\/Mesa_featured.jpg","articleSection":["Patient Care","Research"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/","url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/","name":"FDA approves new drug to treat rare blood cancer myelofibrosis - Mays Cancer Center Annual Report","isPartOf":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/#website"},"primaryImageOfPage":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/#primaryimage"},"image":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2020\/06\/Mesa_featured.jpg","datePublished":"2020-06-14T16:35:23+00:00","dateModified":"2020-06-16T21:00:12+00:00","author":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/#\/schema\/person\/92ba77ef72a0095914424aa87b09c99c"},"breadcrumb":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/#primaryimage","url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2020\/06\/Mesa_featured.jpg","contentUrl":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2020\/06\/Mesa_featured.jpg","width":800,"height":480,"caption":"Ruben Mesa, M.D., FACP"},{"@type":"BreadcrumbList","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2020\/06\/14\/fda-approves-drug-to-treat-blood-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/magazines.uthscsa.edu\/cancer-center\/"},{"@type":"ListItem","position":2,"name":"Mays Cancer Center Annual Report","item":"https:\/\/magazines.uthscsa.edu\/cancer-center\/magazine\/cancer-center\/"},{"@type":"ListItem","position":3,"name":"FDA approves new drug to treat rare blood cancer myelofibrosis"}]},{"@type":"WebSite","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/#website","url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/","name":"Mays Cancer Center Annual Report","description":"Mays Cancer Center Annual Reports","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/magazines.uthscsa.edu\/cancer-center\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/#\/schema\/person\/92ba77ef72a0095914424aa87b09c99c","name":"duncancl","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/4561cd958c8f1ae172cfa6e6a22ea689cad8a0153177b8c4b0997fa83e7bbe33?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4561cd958c8f1ae172cfa6e6a22ea689cad8a0153177b8c4b0997fa83e7bbe33?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4561cd958c8f1ae172cfa6e6a22ea689cad8a0153177b8c4b0997fa83e7bbe33?s=96&d=mm&r=g","caption":"duncancl"},"description":"Catherine Duncan is director of communications for the Office of Institutional Advancement. She also serves as editor and publications director for Salute magazine.","url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/author\/duncancl\/"}]}},"_links":{"self":[{"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/posts\/1765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/comments?post=1765"}],"version-history":[{"count":0,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/posts\/1765\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/media\/1833"}],"wp:attachment":[{"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/media?parent=1765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/categories?post=1765"},{"taxonomy":"magazine","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/magazine?post=1765"},{"taxonomy":"issue-year","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/issue-year?post=1765"},{"taxonomy":"featured-story","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/featured-story?post=1765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}